Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5526_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
31.08.2026
Размер:
29 Мб
Скачать
30
A. Borrelli et al.
Additionally, TIA, by denition, lasts less than 24h; therefore, prolonged symp­toms necessitate the exclusion of an infarction.
Neuroimaging is essential for conrming the diagnosis of infarction. As in other forms of ischemic stroke, the choice of the most appropriate brain imaging tech­nique depends on a multifactorial evaluation. MRI or CT with angiography is indi­cated to exclude atherosclerosis, arterial dissection, or vasospasm. The use of MRI with DWI (diffusion weighted imaging) sequences may be benecial in the acute phase, as it is the most sensitive within the rst 24h. Patients arriving at the emer­gency department in the rst few hours may benet from a CT or MRI with DWI and uid-attenuated inversion recovery (FLAIR) sequences to be evaluated for thrombolysis. However, to date, there is no literature on the use of thrombolysis for this indication, as most patients present to the emergency department hours or even days after symptom onset [19].
The diagnostic workup must include laboratory tests to rule out underlying thrombophilia, such as PT, aPTT, Factor V Leiden, protein C and S activity levels, MTHFR mutations, antithrombin III, antiphospholipid, anticardiolipin, and anti-β2 glycoprotein antibodies, lupus anticoagulant, and homocysteine levels. To exclude cardiac embolism, echocardiography (preferably transesophageal) along with pro­longed electrocardiographic monitoring or Holter electrocardiogram (ECG) is man­datory: these can exclude a right-to-left shunt (patent foramen ovale) or arrythmias such as cardiac brillation [4].
Step 1: Clinical suspicion
Identify key clinical characteristics
– History of migraine with aura, particularly in young females, but not
exclusively
– Episode resembling previous ones, but longer in duration (by denition,
more than 60 min), with the possible addition of the following characteristics:
• Additional symptoms (from the onset or starting progressively)
• Greater intensity of the attack
Step 2: Diagnostic workup
Perform brain imaging: CTA or MRA; MRI with DWI and FLAIR is func- tional in the rst 24h
Conrm infarction: Primarily in the posterior cerebrovascular territory, but not exclusively
Rule out vascular disease (atherosclerosis, arterial dissection, vasospasm)
Assess hypercoagulability
– Laboratory tests: PT, aPTT, Factor V Leiden, protein C and S activity lev-
els, MTHFR mutations, antithrombin III, antiphospholipid, anticardio­lipin, anti-β2 glycoprotein antibodies, lupus anticoagulant, and homocysteine levels.
3 Migrainous Infarction
31
Rule out cardiac embolism (cardiac brillation, right-to-left shunt)
– Transesophageal (preferred) or transthoracic echocardiography – Prolonged ECG or Holter ECG
Consider genetic testing for rare causes of migraine and stroke when appro­priate, such as CADASIL and MELAS
Assess risk factors for stroke:
– Blood pression monitoring – Laboratory testing for dyslipidemia and diabetes – Oral contraception – Smoking

3.7 Management

Antiplatelet therapy with aspirin or clopidogrel is advisable for the prevention of recurrences [4]. Dual antiplatelet therapy has never been studied explicitly in migrainous infarction. However, aspirin and clopidogrel are recommended by the American Heart Association American Stroke Association (AHA/ASA) ASA guidelines for minor non-cardioembolic ischemic stroke or high-risk TIA for a maximum of 90days [40]. They may also be a plausible choice for non- cardioembolic migrainous infarction.
Assessment of modiable cardiovascular risk factors is also essential. As already pointed out, traditional risk factors such as diabetes, hypertension, and dyslipidemia are less frequent (and possibly less signicant) compared to other young stroke patients. At the same time, oral contraception and smoking are more important. Oral contraception is currently contraindicated by the U.S.Medical Eligibility Criteria for Contraceptive Use in patients with migraine with aura, and its discontinuation is recommended [41].
Preventive therapy for migraine is generally advised after ischemic brain events. Although an association between migraine frequency and stroke risk has been observed [42], there is no consistent evidence that migraine prevention reduces the risk of stroke [43]. A 19-year cohort study, however, showed that migraine patients who are treated with a combination of two or more preventive medications have a reduced risk of stroke when compared to patients using only one medication [44]. Further studies are needed to clarify the role of migraine prevention in the risk of ischemic stroke. Calcium channel blockers may be a suitable preventive option for patients with migraine and a history of stroke, due to their vasodilatory effects and anti-ischemic properties, which are mediated by interactions with GABA-A (gamma-aminobutyric acid) receptors in the brain. Melatonin, valproic acid, and onabotulinumtoxinA can be considered safe alternatives.
Regarding acute treatments, extreme caution is advised when using triptans and ergotamines in patients with prolonged aura, due to a potential increased risk of
32
A. Borrelli et al.
stroke [4]. Furthermore, triptans are currently contraindicated in patients with a his­tory of cardiovascular ischemic events, including cerebral infarction.
Most patients have a favorable outcome, with either complete remission or minor residual symptoms. However, some cases of permanent signicant disability have been reported. To the best of our knowledge, only one fatal case has been reported in the literature: a 57-year-old woman who was admitted for a headache of greater intensity than usual, and whose evaluation revealed signs of vasospasm and multifo­cal infarcts in the occipital and insular cortices as well as in the deep white matter [6]. However, this case does not appear to meet all the criteria for migrainous infarc­tion [10], and may be more appropriately classied as a migraine-related stroke with different characteristics.
Rates of complete recovery after migrainous infarction vary widely in the litera­ture. Arboix etal. reported that 67% of their patients were symptom-free at dis­charge, after 9.75±6.2days [30]. In a Scandinavian cohort of 33 patients evaluated after 3months, only 3 (9%) had complete remission, while 28 (85%) had residual symptoms (including visual eld defects), and 2 (6%) had signicant disability— these two cases involved brainstem infarcts, resulting in tetraparesis and cranial nerve involvement [12]. Serrano etal. reported that 67% of patients with migraine­related stroke had mild symptoms at discharge (modied Rankin Scale 0–2), increasing to 71% at 90days and 80% at the end of follow-up (mean: 7.5years; range: 12–240months) [17]. Further data and analyses are needed to better under­stand the prognostic factors and natural history of migrainous infarction.

3.8 Conclusion

Migrainous infarction is a rare ischemic complication of migraine with aura, dened by strict diagnostic criteria. It represents a specic entity within the complex and still largely unexplored relationship between migraine and stroke. Here, we pre­sented an exemplary case along with a discussion of the main clinical and patho­physiological characteristics, including recommendations for diagnostic workup and management. However, these considerations are limited by the current litera­ture, which consists predominantly of case reports and a few case series, with incon­sistent or unveriable adherence to ICHD-3 criteria. Moreover, based on current knowledge, the distinction between migrainous infarction and migraine-related stroke does not appear to inuence the diagnostic approach or management strategy.

References

1. Headache Classication Committee of the International Headache Society (IHS). The interna­tional classication of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
2. Hu X, Zhou Y, Zhao H, Peng C.Migraine and the risk of stroke: an updated meta-analysis of prospective cohort studies. Neurol Sci. 2017;38(1):33–40.
3 Migrainous Infarction
3. Ravi V, Osouli Meinagh S, Bavarsad SR.Reviewing migraine-associated pathophysiology and its impact on elevated stroke risk. Front Neurol. 2024;15:1435208.
4. Chiang CC, Chen SP.Migrainous infarction. In: Handbook of clinical neurology [Internet]. Elsevier; 2024 [cited 2024 Oct 1]. p.465–74. Available from: https://linkinghub.elsevier.com/
retrieve/pii/B9780128233573000215.
5. Tietjen GE, Khubchandani J. Vascular biomarkers in migraine. Cephalalgia. 2015;35(2):95–117.
6. Marshall N, Maclaurin WA, Koulouris G.MRA captures vasospasm in fatal migrainous infarc­tion. Headache. 2007;47(2):280–3.
7. Decima D, Cavallo M, Leotta MR, Gaballo A.Migrainous infarction: association with vascu­lar risk factors in a male subject. Neurol Sci. 2009;30(S1):145–6.
8. Tsai CF, Chen CC, Wang SC, Yip PK. Reversible vasospasm in migrainous infarction. J Ultrasound Med. 2010;29(3):481–4.
9. Vinciguerra L, Cantone M, Lanza G, Bramanti A, Santalucia P, Puglisi V, etal. Migrainous infarc­tion and cerebral vasospasm: case report and literature review. J Pain Res. 2019;12:2941–50.
10. Lebedeva ER, Gurary NM, Olesen J.Diagnosis of migrainous infarction: a case report and analysis of previously published cases. Diagnostics. 2023;13(15):2502.
11. Tzoulis C, Naess H, Thomassen L.Migrainous cerebral infarction in a previously healthy 93-year-old female patient with no risk factors for stroke. Cephalalgia. 2006;26(7):894–5.
12. Laurell K, Artto V, Bendtsen L, Hagen K, Kallela M, Meyer EL, etal. Migrainous infarction: a Nordic multicenter study. Eur J Neurol. 2011;18(10):1220–6.
13. Frigerio R, Santoro P, Ferrarese C, Agostoni E.Migrainous cerebral infarction: case reports. Neurol Sci. 2004;25(S3):s300–1.
14. Khardenavis V, Karthik DK, Kulkarni S, Deshpande A.Cortical laminar necrosis in a case of migrainous cerebral infarction. Case Rep. 2018;2018:bcr.
15. Mancini V, Mastria G, Frantellizzi V, Troiani P, Zampatti S, Carboni S, etal. Migrainous infarc­tion in a patient with sporadic hemiplegic migraine and cystic brosis: a 99mTc-HMPAO brain SPECT study. Headache. 2019;59(2):253–8.
16. Linetsky E, Leker RR, Ben-Hur T. Headache characteristics in patients after migrainous stroke. Neurology. 2001;57(1):130–2.
17. Serrano F, Arauz A, Uribe R, Becerra LC, Mantilla K, Zermeño F.Long-term follow-up of patients with migrainous infarction. Clin Neurol Neurosurg. 2018;165:7–9.
18. Censori B, Partziguian T, Poloni M. Migraine improves after ischemic stroke. J Stroke Cerebrovasc Dis. 2013;22(8):e338–42.
19. Wolf ME, Szabo K, Griebe M, Förster A, Gass A, Hennerici MG, etal. Clinical and MRI char­acteristics of acute migrainous infarction. Neurology. 2011;76(22):1911–7.
20. Kandemir Yılmaz M, Kirikli P.Bilateral occipital infarcts due to persistent migraine with aura in an elderly. Agri. 2024;36(4):281–4.
21. Bylund W, Patrick R, Macdonald A.Detection of migrainous infarction with formal visual eld testing: a case report. Clin Pract Cases Emerg Med. 2020;4(3):366–70.
22. Terrin A, Mainardi F, Maggioni F.The pathological spectrum behind migraine aura status: a case series. Neurol Sci. 2019;40(4):861–4.
23. Morais R, Sobral F, Cunha G, Brito O, Santana I.Advanced MRI study of migrainous infarc­tion presenting as cortical laminar necrosis—case report and literature review. Clin Neurol Neurosurg. 2018;167:82–5.
24. Campagna G, Vickers A, Ponce CMP, Lee AG.Homonymous hemianopsia as the presenting sign of migrainous infarction. Can J Ophthalmol. 2018;53(6):e229–32.
25. Renard D, Nerrant E, Freitag C.Early recurrence of migrainous infarction. Acta Neurol Belg. 2015;115(4):675–6.
26. Lai TH, Hong CT.Prolonged symptoms in sporadic hemiplegic migraine: aura or migrainous infarction? Acta Neurol Taiwan. 2012;21(3):129–32.
27. Arai S, Utsunomiya H, Arihiro S, Arakawa S.Migrainous infarction in an adult: evalua­tion with serial diffusion-weighted images and cerebral blood ow studies. Radiat Med. 2008;26(5):313–7.
28. Liang Y, Scott TF.Migrainous infarction with appearance of laminar necrosis on MRI.Clin Neurol Neurosurg. 2007;109(7):592–6.
33
34
29. Tang SC, Jeng JS, Liu HM, Yip PK.Migrainous infarction involving two different arterial ter­ritories: report of two cases. Acta Neurol Taiwan. 2004;13(1):20–3.
30. Arboix A, Massons J, García-Eroles L, Oliveres M, Balcells M, Targa C. Migrainous cerebral infarction in the Sagrat Cor Hospital of Barcelona stroke registry. Cephalalgia. 2003;23(5):389–94.
31. Sacquegna T, Andreoli A, Baldrati A, Lamieri C, de Carolis P, Pasquale GD, etal. Ischemic stroke in young adults: the relevance of migrainous infarction. Cephalalgia. 1989;9:255–8.
32. Moen M, Levine SR, Newman DS, Dull-Baird A, Brown GG, Welch KM.Bilateral posterior cerebral artery strokes in a young migraine sufferer. Stroke. 1988;19(4):525–8.
33. Jacob MA, Ekker MS, Allach Y, Cai M, Aarnio K, Arauz A, etal. Global differences in risk factors, etiology, and outcome of ischemic stroke in young adults—a worldwide meta- analysis. Neurology. 2022;98(6):e573–88.
34. Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T.Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009;339:b3914.
35. Zhao W, Wang D, Tan Y, Yang J, Zhang S.Migraine and the correlation between stroke: a sys­tematic review and meta-analysis. Medicine (Baltimore). 2024;103(45):e40315.
36. Roberto G, Raschi E, Piccinni C, Conti V, Vignatelli L, D’Alessandro R, etal. Adverse cardio­vascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia. 2015;35(2):118–31.
37. Petersen CL, Hougaard A, Gaist D, Hallas J.Risk of stroke and myocardial infarction among initiators of triptans. JAMA Neurol. 2024;81(3):248.
38. Wang Z, VanderPluym JH, Halker Singh RB, Alsibai RA, Roellinger DL, Firwana M, etal. Safety of triptans in patients who have or are at high risk for cardiovascular disease. Mayo Clin Proc. 2024;99(11):1722–31.
39. Nadarajan V, Perry RJ, Johnson J, Werring DJ.Transient ischaemic attacks: mimics and cha­meleons. Pract Neurol. 2014;14(1):23.
40. Kleindorfer DO, Towghi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, etal. 2021 guideline for the prevention of stroke in patients with stroke and transient isch­emic attack: a guideline from the American Heart Association/American Stroke Association. Stroke [Internet]. 2021 [cited 2024 Nov 15];52(7). Available from: https://www.ahajournals.
org/doi/10.1161/STR.0000000000000375.
41. Nguyen AT, Curtis KM, Tepper NK, Kortsmit K, Brittain AW, Snyder EM, etal. U.S. medi­cal eligibility criteria for contraceptive use, 2024. MMWR Recomm Rep. 2024;73(4):1–126.
42. Kurth T, Schürks M, Logroscino G, Buring JE.Migraine frequency and risk of cardiovascular disease in women. Neurology. 2009;73(8):581–8.
43. Gryglas A, Smigiel R.Migraine and stroke: what’s the link? What to do? Curr Neurol Neurosci Rep. 2017;17(3):22.
44. Liao CC, Chien CH, Shih YH, Tsai FJ, Li JM.Acupuncture is effective at reducing the risk of stroke in patients with migraines: a real-world, large-scale cohort study with 19-years of follow-up. Int J Environ Res Public Health. 2023;20(3):1690.
A. Borrelli et al.
Chapter 4
Migraine Aura-Triggered Seizure
IlariaNotaristefano , ValentinaBaglioni , andVincenzoGuidetti

4.1 Introduction

A migraine aura-triggered seizure, formerly known as migralepsy, is a rare condi­tion characterized by a seizure occurring during or within 1h after a migraine attack with aura [1]. Lennox and Lennox rst described this condition in their textbook Epilepsy and Related Disorders, reporting a case of “ophthalmic migraine with per­haps nausea and vomiting followed by symptoms characteristic of epilepsy” [2].
The term migralepsy is a historical portmanteau of migraine and epilepsy, coined by Dr. Douglas Davidson to describe this phenomenon better. Notably, such cases are more common in children than in adults [3]. However, due to sig­nicant diagnostic confusion caused by the term migralepsy, it has been replaced by migraine aura-triggered seizure in more recent classications. The original term led to misdiagnosis in numerous cases where patients had both migraine with aura and epilepsy, resulting in an inaccurate classication of their condition. Additionally, visual migraine aura and occipital seizures can be mistaken for one another, particularly in cases of prolonged seizures [4]. Although headaches and seizures are, respectively, the rst and third most common reasons for a referral from a general practitioner to a neurologist [5], migraine aura-triggered seizure remains a rare condition [6].
This chapter aims to clarify the nature of this condition, including its character­istics, diagnostic challenges, and key differences from other similar disorders.
I. Notaristefano · V. Baglioni · V. Guidetti (*) Child and Adolescent Neuropsychiatry, Sapienza University of Rome, Rome, Italy
Switzerland AG 2026 D. Uludüz et al. (eds.), Rare Causes of Headache Disorders, Headache,
https://doi.org/10.1007/978-3-032-10242-3_4
35© The Author(s), under exclusive license to Springer Nature
36
I. Notaristefano et al.

4.2 Pathophysiology

The pathophysiological causes underlying migraine aura-triggered seizures are still unclear. For this condition to arise, both a migraine aura that induces rapid shifts in cortical excitability and a brain predisposed to synchronized discharges, as seen in epilepsy, must be present. Recent research suggests that both migraine and epilepsy may share a common underlying mechanism of neocortical hyperexcitability, which—when combined with specic genetic and molecular predispositions—can lead to distinct downstream phenomena. In epilepsy, this hyperexcitability is thought to produce a paroxysmal depolarizing shift that directly triggers a seizure, whereas, in migraine, it evolves into cortical spreading depression (CSD), which is subsequently followed by cortical suppression [7].
Moreover, the hypothesis that migraine aura may represent a preictal state fur­ther unies these observations. According to this view, the neurovascular coupling mechanisms that underlie the migraine aura—beginning with an initial wave of hyperexcitability and followed by massive ionic shifts across neuronal mem­branes—can facilitate seizure onset in a cortex already predisposed to epilepsy. Essentially, when the rapid changes induced by a migraine aura occur in a brain susceptible to synchronized discharges, they may pave the way for a seizure [8, 9]. Thus, both hypotheses converge on the idea that a hyperexcitable cortex is central to the pathogenesis of these conditions. Depending on individual susceptibility and the dynamics of the underlying neurovascular processes, this hyperexcitability may manifest as either a migraine with aura, an epileptic seizure, or even a scenario where the migraine aura itself triggers the seizure.
An alternative hypothesis proposes that aura-triggered seizures represent a form of reex epilepsy, in which activation of a task-specic neural network induces excessive neuronal synchronization, ultimately leading to a seizure. However, this explanation appears less effective in accounting for the observed phenomena [8].

4.3 Case Presentation

An 11-year-old girl has experienced recurrent headaches since she was 4years old. In her early years, the headaches were relatively mild in severity and accompanied by nausea and showed improvement with acute treatment with paracetamol. In her family history, a high frequency of migraine and epileptic conditions was reported: her mother suffers from migraine with aura and vasculitis, her maternal grand­mother has migraine without aura, and an aunt has been diagnosed with epilepsy. By the age of eight, the patient’s headaches had become more frequent and severe, prompting a thorough clinical evaluation. She was diagnosed with migraine with aura following the International Classication of Headache Disorders-III (ICHD-3) criteria. Her migraine episodes are described as intense, throbbing pain localized to the right frontal and temporal regions, often accompanied by photophobia,
4 Migraine Aura-Triggered Seizure
phonophobia, facial ushing, and nausea. These attacks occurred approximately two to four times per month and were disruptive enough to interfere with her daily activities signicantly. In response to her worsening symptoms, prophylactic treat­ment with unarizine was started, leading to a notable improvement in her condi­tion. Given the strong family history of migraines, a genetic diagnostic evaluation was performed by a Next Generation System (NGS) panel to explore potential inherited causes. However, the genetic investigation revealed no pathogenic variants among the genes examined. Despite the improvement with unarizine, at the age of 10, the patient experienced 2 distinct episodes where her typical aura was followed in less than 20min by a sudden loss of consciousness, with a tonic–clonic seizure, which resolved spontaneously. A similar episode occurred during a subsequent febrile illness the following year. In light of these seizure episodes, further neuro­logical evaluation was pursued. An interictal electroencephalography (EEG) revealed the presence of sharp waves, in particular in the centrotemporal regions, while a brain MRI returned normal ndings.
These investigations led to the initiation of topiramate therapy at a dose of 2mg/ kg/day. More recent EEG assessments have not demonstrated any epileptiform abnormalities, and, currently, the patient remains free from clinical seizures.
37

4.4 Case Discussion

This clinical case illustrates a migraine aura-triggered seizure, which led to the young girl’s diagnosis. Several key features can be identied:
1. The presence of migraine with aura symptoms (including throbbing pain, photo-
phobia, phonophobia, facial ushing, and nausea).
2. The occurrence of an epileptic seizure within 1h of the headache onset.
3. A favorable response to antiseizure medication.
4.5 Diagnostic Criteria andDifferential Diagnosis
Per ICHD-3 [1], the diagnosis of migraine aura-triggered seizure is possible in case of:
A. A seizure fullling diagnostic criteria for one type of epileptic attack, and crite-
rion B below.
B. Occurring in a patient with 1.2 Migraine with aura, and during or within 1h
after an attack of migraine with aura.
C. Not better accounted for by another ICHD-3 diagnosis.
As observed, migraine aura-triggered seizure is a diagnosis of exclusion, mean­ing that other potential conditions must be ruled out rst. Therefore, it is essential to
38
I. Notaristefano et al.
Table 4.1
Differential features of migraine visual aura and occipital lobe seizures
Migraine visual aura [11] Occipital lobe seizure [12] Fluttering, uncolored, zigzag
Develops gradually over 5–30min Acute onset is rare Total duration <60min Emerges in the center of the visual eld and gradually shifts to the outer edges of a visual hemi-eld, often leaving a blind spot Followed by migraine without aura Spots, circles, and beads with or without colors may be experienced, but not dominant
Mainly colored circular patterns Develop rapidly within seconds Brief duration (2–3min) Frequently appear in the outer regions of a temporal visual hemi-eld, increasing in size and multiplying during the seizure, often shifting horizontally toward the opposite side Postictal headache frequently occurs 3–15min after the seizures end Progress to other occipital and extra-occipital manifestations and convulsions
exclude confounding factors such as visual phenomena of epileptic origin (e.g., occipital lobe epilepsy), syncope, and psychogenic non-epileptic seizures (PNES) [10]. Additionally, for this diagnosis, the association between epileptic seizures and migraine without aura remains unclear.
In particular, to differentiate visual aura from visual epileptic phenomena, it is necessary to know their features, as described in Table4.1.
Also, the Visual Aura Rating Scale (VARS) is a validated instrument in which scores of ±5 are considered indicative of migraine aura [13].
To simplify the approach, a diagnostic algorithm has been proposed for cases suspected of migraine aura-triggered seizures.

4.6 Diagnostic Algorithm

Step 1: Clinical suspicion.
• Identify key symptoms:
– Migraine with aura (evaluate frequency and intensity). – Epileptic seizure during or within 1h after an attack of migraine with aura.
Step 2: Initial diagnostic workup.
• Perform EEG, if possible, during migraine.
• Brain imaging.
Step 3: Additional diagnostic evaluations for the differential diagnosis.
• Performed VARS scale.
– Score 5 points: probably migraine visual aura. – Score 5 points: improbable migraine visual aura.
• Differential diagnosis from syncope and PNES.
4 Migraine Aura-Triggered Seizure
39
Step 3: Conrm diagnosis.
• Conrm diagnosis of exclusion, considering that it is rarer than the other conditions.

4.7 Management

Nowadays, there is no specic treatment for migraine aura-triggered seizures. Some researchers emphasize the importance of preventing migraine onset; however, most patients respond poorly to traditional migraine treatments such as unarizine and propranolol [14]. Some evidence suggests that opioids, when used as monotherapy, may effectively prevent both migraines and subsequent seizures [15]. Other clini­cians highlight the strong clinical and EEG response to antiseizure treatment [14], with the choice of medication depending on the type of seizures presented. Among available treatments, topiramate has demonstrated efcacy in both migraine and epilepsy through randomized controlled trials and is approved for both conditions [16]. For these reasons, it is often the preferred therapeutic option in this context.

4.8 Conclusion

Migraine aura-triggered seizure remains a rare and complex phenomenon at the intersection of migraine and epilepsy. Despite historical diagnostic confusion sur­rounding the term “migralepsy,” this condition is now recognized as a diagnosis of exclusion, requiring careful differentiation from other pathologies. While the under­lying mechanisms remain incompletely understood, research suggests that cortical hyperexcitability plays a central role, with migraine aura potentially acting as a seizure trigger in predisposed individuals. Management remains challenging, with conventional migraine prophylaxis often proving insufcient. However, antiseizure drugs—particularly topiramate—have shown efcacy in reducing both migraine attacks and seizure occurrence, making them a preferred therapeutic option.

References

1. Headache Classication Committee of the International Headache Society (IHS). The interna­tional classication of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. https://
doi.org/10.1177/0333102417738202. PMID: 29368949.
2. Lennox WG.Epilepsy and related disorders. Boston: Little; 1960.
3. Davies PTG, Panayiotopoulos CP. Migraine triggered seizures and epilepsy triggered head­ache and migraine attacks: a need for re-assessment. J Headache Pain. 2011;12(3):287–8.
https://doi.org/10.1007/s10194- 011- 0344- 2. PMID: 21516466.